Program
ZP6590
A development code. Also written as “ZP6590, solution for injection”.
Its studies are mostly in Obesity, led by Zealand Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zealand Pharma | 11 open or running | early phase 1since Jul 16, 2026 | Jul 16, 2026 | Sep 6, 2027early phase 1 · NCT07721597 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2026First study: early phase 1 study in OverweightFirst studyNCT07721597 · 88 planned · Germany
Ahead
- Sep 6, 2027Primary completion: early phase 1 study in OverweightNCT07721597
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07721597Overweight · Germany | Early 1 | Recruiting | Sep 6, 2027 | 88 |
How it is read
Names in the registry
- “ZP6590, solution for injection”, 1 entry
Codes read as this program: ZP6590.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.